At present, the effect of ICB for cancer patients is primarily predicted by the measurements of programmed cell death 1 ligand 1 (PD-L1) expression levels [14], microsatellite instability (MSI) or mismatch repair-deficient (dMMR) [15], and the tumor mutational burden (TMB) [16–19], to name a few. Here, CD274 is linked to neoplasm.